Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications

Applied Health Economics and Health Policy

Volumn 15, Issue 1, 2017, Pages 85-93

  Kostić, Marina ^a   Djakovic, Ljiljan ^b   Šujić, Raša ^b   Godman, Brian ^c,d,e   Janković, Slobodan M ^a  

^a University of Kragujevac Medical Faculty   (Serbia)

^b Association of patients with Crohn s disease and Ulcerative colitis   (Serbia)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; C REACTIVE PROTEIN; CREATININE; GLUCOSE; INFLIXIMAB;

ABDOMINAL RADIOGRAPHY; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOLOGICAL THERAPY; COLON BIOPSY; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; COST OF ILLNESS; CREATININE BLOOD LEVEL; CROHN DISEASE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION COST; HUMAN; INCOME; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT TRANSPORT; PHYSIOTHERAPY; SERBIA; STRUCTURED QUESTIONNAIRE; THORAX RADIOGRAPHY; ULCERATIVE COLITIS; X-RAY COMPUTED TOMOGRAPHY; COLITIS, ULCERATIVE; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; MIDDLE AGED; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; DELIVERY OF HEALTH CARE; FEMALE; FINANCING, PERSONAL; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; SERBIA; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84984787866     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-016-0272-z     Document Type: Article

References (31)

1. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–17.
2. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53(10):1471–8.
3. Bodger K. Cost of illness of Crohn’s disease. Pharmacoeconomics. 2002;20:639–52.
4. Williams JG, Roberts SE, Ali MF, Cheung WY, Cohen DR, Demery G, Edwards A, Greer M, Hellier MD, Hutchings HA, Ip B, Longo MF, Russell IT, Snooks HA, Williams JC. Gastroenterology services in the UK. The burden of disease, and the organization and delivery of services for gastrointestinal and liver disorders: a review of the evidence. Gut. 2007;56:1–113.
5. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol. 2003;98:1064–72.
6. Cohen RD. The quality of life in patients with Crohn’s disease. Aliment Pharmacol Ther. 2002;16:1603–9.
7. Ganz ML, Sugarman R, Wang R, Hansen BB, Hakan-Bloch J. The economic and health-related impact of Crohn’s disease in the United States: evidence from a nationally representative survey. Inflamm Bowel Dis. 2016;22(5):1032–41.
8. Burisch J, Vardi H, Pedersen N, Brinar M, Cukovic-Cavka S, Kaimakliotis I, et al. Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study. Inflamm Bowel Dis. 2015;21(1):121–31.
9. Buchanan J, Wordsworth S, Ahmad T, Perrin A, Vermeire S, Sans M, Taylor J, Jewell D. Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers. J Crohns Colitis. 2011;5(4):301–16.
10. Brodszky V, Rencz F, Pentek M, Baji P, Lakatos PL, Gulacsi L. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):119–25.
11. Strik AS, Bots SJ, D’Haens G, Lowenberg M. Optimization of anti-TNF therapy in patients with inflammatory bowel disease. Expert Rev Clin Pharmacol. 2016;9(3):429–39.
12. Huoponen S, Blom M. A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases. PLoS One. 2015;10(12):e0145087.
13. Feagan BG. Review article: economic issues in Crohn’s disease—assessing the effects of new treatments on health-related quality of life. Aliment Pharmacol Ther. 1999;13(s4):29–37.
14. Kostić M, Jovanović S, Tomović M, Milenković MP, Janković SM. Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: a Markov model based on data from Serbia, country in socioeconomic transition. Vojnosanit Pregl. 2014;71(2):144–8.
15. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206.
16. Matusewicz W, Godman B, Pedersen HB, Furst J, Gulbinovic J, Mack A, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755–8.
17. Stark R, König HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics. 2006;24(8):797–814.
18. Severs M, Petersen RE, Siersema PD, Mangen MJ, Oldenburg B. Self-reported health care utilization of patients with inflammatory bowel disease correlates perfectly with medical records. Inflamm Bowel Dis. 2016;22(3):688–93.
19. Questionnaire. Available at: http://www.ukuks.org/anketa/poruka.php. Accessed 18 Nov 2014.
20. Anonymous. Tariff Book of Health Care Services in Health Facilities of Republic of Serbia. Belgrade: Republic Institute for Health Insurance; 2014.
21. The Prices of Medication in Serbia, from december/2014; Official Gazette of Republic of Serbia 133/2014.
22. Pension and Disability Insurance Fund, Republic of Serbia; Available at: http://www.pio.rs/lat/novcane-naknade.html.
23. Paris V, Belloni A. Value in pharmaceutical pricing. Available at URL: http://www.oecd-ilibrary.org/docserver/download/5k43jc9v6knx.pdf?expires=1454876546&id=id&accname=guest&checksum=87065DEF51331D5A659CC1917CCFCEC7.
24. Burisch J, Jess T, Martinato M, Lakatos PL, ECCO—EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7(4):322–37.
25. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, Finkelstein JA. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907–13.
26. Monstad I, Hovde O, Solberg IC, Moum BA. Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies. Ann Gastroenterol. 2014;27(2):95–104.
27. Hovde Ø, Huppertz-Hauss G, Høivik ML, Moum B. Clinical course, treatment strategies, social and economic impact of ulcerative colitis: an overview. Austin J Gastroenterol. 2014;1(4):1017.
28. Høivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M, Bernklev T, IBSEN Group. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut. 2013;62:368–375.
29. Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, Glasgow KW, Fernandes A, Ghosh S. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26(11):811–7.
30. Mack A. Norway, biosimilars in different funding systems. What works? Generics Biosimilars Initiat J (GaBI J). 2015;4(2):90–2.
31. Faleiros DR, Alvares J, Almeida AM, de Araujo VE, Andrade EI, Godman BB, et al. Budget impact analysis of medicines: updated systematic review and implications. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):257–66.